- All patients currently enrolled in both arms of ARMOR will be given the opportunity to transition to the new open label part with 300mg BID Aramchol Acid, allowing a potential first readout of the ...
Histological improvement in fibrosis (≥1 stage) was demonstrated in 39% of subjects according to NASH CRN, in 61% of subjects by ranked assessment with a highly statistically significant (p<0.0001) ...
TEL AVIV, Israel, Dec. 17, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback